Biotest AG: Biotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University
News: Biotest AG / Key word(s): Research Update
Biotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University
- Trial investigates personalized treatment approaches with Biotest's Pentaglobin(R) in patients with abdominal inflammation (peritonitis)
- Novel testing systems included to determine individual patient risks
Prof Gernot Marx from the Aachen University (RWTH Aachen), the coordinating investigator of the study mentioned "Sepsis or even peritonitis with an abdominal focus is such a heterogeneous syndrome that new and more individualized treatments are needed. An aim of the study is to identify which patient needs which kind of treatment with the immuno-modulatory substance Pentaglobin(R). Currently we only have well established antibiotics and surgical interventions to combat the disastrous systemic infections and subsequent inflammation. Personalized treatments to normalize the immune response and to overcome the inflammatory dysregulation are urgently needed."
The subgroups identified in the PEPPER trial will enable physicians to better understand how to use immuno-modulatory treatment in this particular patient group. Results from this trial can be an important step towards a more personalized and hence successful treatment of peritonitis. The trial has been approved by the Ethics Committee at Aachen University and by Paul Ehrlich Institute (PEI) in Germany.
Further partners in the trial are Curetis GmbH for molecular diagnostic analysis and Sphingotec GmbH for the determination of additional diagnostic parameters.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|